```
=> d his

     (FILE 'HOME' ENTERED AT 17:29:25 ON 24 MAR 2005)

     FILE 'REGISTRY' ENTERED AT 17:29:34 ON 24 MAR 2005
L1              STRUCTURE UPLOADED
L2            1 S L1 SAM
L3           70 S L1 FUL

     FILE 'HCAPLUS' ENTERED AT 17:30:19 ON 24 MAR 2005
L4           27 S L3
L5           24 L4 AND PD<20030324
L6            0 L5 AND INFLAMM?
L7            0 L5 AND CD1
L8           22 L5 AND MTP
```















chain nodes :
14 15 16 17 18 19 20 21 49 50 56 57 58 59 60 61 62 63
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 22 23 24 25 26 27 28 29 30 31
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48
chain bonds :
7-14 7-49 14-15 15-16 16-17 17-18 18-19 19-20 20-21 20-22 23-33 56-57
56-63 57-58 58-59 59-60 59-61 59-62
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 8-10 9-13 10-11 11-12 12-13
22-23 22-27 23-24 24-25 25-26 26-27 28-29 28-33 29-30 30-31 31-32 32-33
34-35 34-39 35-36 36-37 37-38 38-39 40-41 40-45 41-42 42-43 43-44 43-46
44-45 44-48 46-47 47-48
exact/norm bonds :
4-7 5-9 7-8 7-49 17-18 18-19 19-20 20-21 34-35 34-39 35-36 36-37 37-38
38-39 40-41 40-45 41-42 42-43 43-44 43-46 44-45 44-48 46-47 47-48 56-57
56-63 57-58
exact bonds :
7-14 14-15 15-16 16-17 20-22 23-33 58-59 59-60 59-61 59-62
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-10 9-13 10-11 11-12 12-13 22-23 22-27
23-24 24-25 25-26 26-27 28-29 28-33 29-30 30-31 31-32 32-33

G1:[*1-*2],[*3-*4]

G2:[*5],[*6]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom
28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom
37:Atom 38:Atom 39:Atom 40:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:Atom
46:Atom 47:Atom 48:Atom 49:CLASS 50:Atom 56:CLASS 57:CLASS 58:CLASS
59:CLASS 60:CLASS 61:CLASS 62:CLASS 63:CLASS
Generic attributes :
50:
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

L8 ANSWER 1 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:875344 HCAPLUS Full-text
DOCUMENT NUMBER: 138:378966
TITLE: Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: comparison with an **MTP** inhibitor
AUTHOR(S): Funatsu, Toshiyuki; Kakuta, Hirotoshi; Takasu, Toshiyuki; Miyata, Keiji
CORPORATE SOURCE: Institute for Drug Discovery Research, Pharmacology Laboratories, Yamanouchi Pharmaceutical Co., Ltd., Ibaraki, Tsukuba, 3058585, Japan
SOURCE: European Journal of Pharmacology (**2002**), 455(2-3), 161-167
CODEN: EJPHAZ; ISSN: 0014-2999
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We investigated the effects of atorvastatin, a widely used 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor, and BMS-201038, a microsomal triglyceride transfer protein (**MTP**) inhibitor, in sucrose-fed hypertriglyceridemic rats to determine whether the activation of beta-oxidation by these compds. plays a role in their hypotriglyceridemic effect. The decrease in plasma triglyceride concentration and post-Triton very low-d. lipoprotein (VLDL) triglyceride concentration, a measure of hepatic triglyceride secretion, by atorvastatin (30 mg/kg p.o.) for 2 wk was to approx. the same degree as those by BMS-201038 (0.3 mg/kg). Atorvastatin (30 mg/kg) increased hepatic beta-oxidation activity by 54% ($P<0.01$), while BMS-201038 (0.3 mg/kg) had no significant effect. Atorvastatin decreased hepatic triglyceride, fatty acid and cholesteryl ester concns. by 21% to 39%, whereas BMS-201038 increased these variables by 28% to 307%. In the atorvastatin-treated groups, a significant relation was seen not only between hepatic beta-oxidation activity and hepatic triglyceride concentration ($R2=0.535$, $P<0.01$), but also between hepatic and plasma triglyceride concns. ($R2=0.586$, $P<0.01$). No effect of atorvastatin on hepatic fatty acid synthesis was observed These results indicate that the activation of hepatic beta-oxidation by atorvastatin may contribute to the decrease in hepatic triglyceride concentration, leading to its hypotriglyceridemic effect.

IT **182431-12-5**, BMS-201038
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(atorvastatin increases hepatic fatty acid β-oxidation in sucrose-fed rats and comparison with an **MTP** inhibitor BMS-201038)

RN 182431-12-5 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:591918 HCAPLUS Full-text
DOCUMENT NUMBER: 137:159310
TITLE: Activators of peroxisome proliferator-activated receptor (PPAR) α for treatment of fatty liver, and hypolipemic agents containing the activators and **MTP** inhibitors
INVENTOR(S): Noguchi, Takeshi; Hirota, Kotaro; Tanaka, Masashi
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002220345	A2	20020809	JP 2001-15602	20010124 <--
PRIORITY APPLN. INFO.:			JP 2001-15602	20010124

AB Title activators are useful for prophylactic and/or therapeutic treatment of fatty liver in patients under treatment with microsomal triglyceride transfer protein (**MTP**) inhibitors. Thus, oral administration of BAY 13-9952 at 10 mg/kg and clinofibrate at 30 mg/kg in high sucrose-loaded rats resulted in serum triglyceride 23.0 mg/dL, serum cholesterol 32.8 mg/dL, liver triglyceride 24.6 mg/g, and liver cholesterol 3.4 mg/g.
IT **182431-12-5**, BMS 201038

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(hypolipemic agents containing peroxisome proliferator-activated receptor α activators and **MTP** inhibitors causing no fatty liver)

RN 182431-12-5 HCAPLUS

CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **182431-12-5D**, BMS 201038, mixts. contg.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hypolipemic agents containing peroxisome proliferator-activated receptor α activators and **MTP** inhibitors causing no fatty liver)

RN 182431-12-5 HCAPLUS

CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L8 ANSWER 3 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:445786 HCAPLUS Full-text
DOCUMENT NUMBER: 135:327129
TITLE: Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells
AUTHOR(S): Funatsu, T.; Suzuki, K.; Goto, M.; Arai, Y.; Kakuta, H.; Tanaka, H.; Yasuda, S.; Ida, M.; Nishijima, S.; Miyata, K.
CORPORATE SOURCE: Pharmacology Laboratory, Institute for Drug Discovery Research, Tsukuba-shi, Ibaraki, 3058585, Japan
SOURCE: Atherosclerosis (Shannon, Ireland) (**2001**), 157(1), 107-115
CODEN: ATHSBL; ISSN: 0021-9150
PUBLISHER: Elsevier Science Ireland Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Atorvastatin is a new HMG-CoA reductase inhibitor that strongly lowers plasma cholesterol and triglyceride (TG) levels in humans and animals. Since previous data indicated that atorvastatin has prolonged inhibition of hepatic cholesterol synthesis, we tested whether this longer duration of inhibitory effect on cholesterol synthesis decreased hepatic lipoprotein secretion in vitro. We used the HepG2 hepatoma cell line to: (1) determine the time required until levels of secreted apo B-100 and TG declined significantly, (2) examine the relation to the mass of cellular cholesteryl ester (CE) and (3) test microsomal triglyceride transfer protein (**MTP**) activity which leads to decreased apo B-100 production Although atorvastatin significantly inhibited cholesterol synthesis in HepG2 cells regardless of treatment duration (1, 14 or 24 h), it did not inhibit TG synthesis. Apo B-100 and TG secretion were unchanged after 1-h atorvastatin treatment, but declined significantly after

24-h treatment. Atorvastatin treatment also reduced cellular CE mass, exhibiting both time- and dose-dependency. Mevalonolactone, a product of HMG-CoA reductase, attenuated the inhibitory effects of atorvastatin. Atorvastatin strongly reduced mRNA levels of **MTP**, whereas it did not inhibit **MTP** activity as measured by TG transfer assay between liposomes. Simvastatin also induced treatment- and time-dependent redns. in apo B-100, whereas the **MTP** inhibitor BMS-201038 exhibited no time dependency, instead inhibiting this variable even on 1-h treatment. These results indicate that reduced apo B-100 secretion caused by atorvastatin is a secondary result owing to decreased lipid availability, and that atorvastatin's efficacy depends on the duration of cholesterol synthesis inhibition in the liver.

IT **182431-12-5**, BMS 201038
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BMS 201038; prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells)

RN 182431-12-5 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:356207 HCAPLUS Full-text
DOCUMENT NUMBER: 134:348283
TITLE: Methods of administering apolipoprotein B

secretion/microsomal triglyceride transfer protein inhibitors

INVENTOR(S): Chang, George; Vincent, John

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 42 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1099442	A2	20010516	EP 2000-309907	20001108 <--
EP 1099442	A3	20021204		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2325201	AA	20010510	CA 2000-2325201	20001108 <--

PRIORITY APPLN. INFO.: US 1999-164579P P 19991110

OTHER SOURCE(S): MARPAT 134:348283

AB Methods are provided for administration of apoB secretion/**MTP** inhibitors. The methods comprise administration prior to or during a period of somnolence. Preparation of inhibitors is also described.

IT **182431-12-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(apolipoprotein B secretion/microsomal triglyceride transfer protein inhibitor administration prior to or during somnolence period)

RN 182431-12-5 HCAPLUS

CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





L8 ANSWER 5 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:356206 HCAPLUS Full-text
DOCUMENT NUMBER: 134:348292
TITLE: Methods and pharmaceutical compositions containing Apo B secretion/microsomal triglyceride transfer protein inhibitors and anti-obesity agents for the treatment of obesity
INVENTOR(S): Morgan, Bradley Paul; Swick, Andrew Gordon
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1099441	A2	20010516	EP 2000-309753	20001103 <--
EP 1099441	A3	20021204		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2324801	AA	20010510	CA 2000-2324801	20001031 <--
BR 2000005318	A	20010807	BR 2000-5318	20001109 <--
JP 2001139491	A2	20010522	JP 2000-344124	20001110 <--
PRIORITY APPLN. INFO.:			US 1999-164780P P	19991110
OTHER SOURCE(S):	MARPAT 134:348292			

AB The invention provides methods and pharmaceutical compns. contg. Apo B secretion/**MTP** inhibitors and anti-obesity agents for the treatment of obesity an animal, preferably a mammal including a human subject, a companion animal, or livestock, using an apo B secretion/ **MTP** inhibitor and an anti-obesity agent. The invention further provides to a kit comprising an amount of an apolipoprotein B secretion/microsomal triglyceride transfer protein inhibitor and a pharmaceutically acceptable carrier, vehicle or diluent in a first unit dosage form; an amount of an anti-obesity agent and a pharmaceutically acceptable carrier, vehicle or diluent in a second unit dosage form; and a container.

IT **182431-12-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(apo B secretion/**MTP** inhibitors-containing pharmaceutical compns. and anti-obesity agents for the treatment of obesity)

RN 182431-12-5 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L8 ANSWER 6 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:356205 HCAPLUS Full-text
DOCUMENT NUMBER: 134:361376
TITLE: Use of apo B secretion/**MTP** inhibitors for reducing intestinal fat absorption
INVENTOR(S): Chandler, Charles Edward; Hickman, Mary Anne; Lundy, Kristin Marie; Morgan, Bradley Paul
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
EP 1099439	A2	20010516	EP 2000-309721	20001103	<--
EP 1099439	A3	20030326			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
CA 2324800	AA	20010510	CA 2000-2324800	20001031	<--
ZA 2000006419	A	20020508	ZA 2000-6419	20001108	<--
NZ 508059	A	20021126	NZ 2000-508059	20001109	<--
JP 2001172180	A2	20010626	JP 2000-342892	20001110	<--

PRIORITY APPLN. INFO.: US 1999-164547P P 19991110
OTHER SOURCE(S): MARPAT 134:361376
GI



I



II

AB Microsomal triglyceride transfer protein apolipoprotein B (apo B) secretion/microsomal triglyceride transfer protein (**MTP**) inhibitors are used for reducing intestinal fat absorption in animals and humans. Antiobesity agents may be included in the formulations. I and II reduced intestinal fat absorption in dogs by 49% and 26%, resp.

IT **182431-12-5**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(apo B secretion/**MTP** inhibitors for reducing intestinal fat absorption)

RN 182431-12-5 HCAPLUS

CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)





L8 ANSWER 7 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:356204 HCAPLUS Full-text
DOCUMENT NUMBER: 134:361375
TITLE: Use of apo B secretion/**MTP** inhibitors as antiobesity agents
INVENTOR(S): Hickman, Mary Anne; Lundy, Kristin Marie; Morgan, Bradley Paul
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
EP 1099438	A2	20010516	EP 2000-309705	20001103	<--
EP 1099438	A3	20030319			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
CA 2325282	AA	20010510	CA 2000-2325282	20001108	<--
ZA 2000006417	A	20020508	ZA 2000-6417	20001108	<--
NZ 508061	A	20020426	NZ 2000-508061	20001109	<--
AU 777542	B2	20041021	AU 2000-71519	20001109	
JP 2001181209	A2	20010703	JP 2000-344128	20001110	<--
PRIORITY APPLN. INFO.:			US 1999-164513P P	19991110	

OTHER SOURCE(S): MARPAT 134:361375
GI



I

AB The invention relates to methods and pharmaceutical compns. useful in reducing food intake in an animal, preferably a mammal including a human subject or a companion animal, using a microsomal triglyceride transfer protein apolipoprotein B (apo B) secretion/microsomal triglyceride transfer protein (**MTP**) inhibitor. Antiobesity agents may be included in the formulations. I and II reduced food intake in dogs by 58% and 30%, resp.

IT **182431-12-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(apo B secretion/**MTP** inhibitors as antiobesity agents)
RN 182431-12-5 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L8 ANSWER 8 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:124741 HCAPLUS Full-text
DOCUMENT NUMBER: 134:304970
TITLE: A Novel Series of Highly Potent Benzimidazole-Based Microsomal Triglyceride Transfer Protein Inhibitors
AUTHOR(S): Robl, Jeffrey A.; Sulsky, Richard; Sun, Chong-Qing; Simpkins, Ligaya M.; Wang, Tammy; Dickson, John K., Jr.; Chen, Ying; Magnin, David R.; Taunk, Prakash; Slusarchyk, William A.; Biller, Scott A.; Lan, Shih-Jung; Connolly, Fergal; Kunselman, Lori K.; Sabrah, Talal; Jamil, Haris; Gordon, David; Harrity, Thomas W.; Wetterau, John R.
CORPORATE SOURCE: The Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-5400, USA
SOURCE: Journal of Medicinal Chemistry (**2001**), 44(6), 851-856
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of benzimidazole-based analogs of the potent **MTP** inhibitor BMS-201038 were discovered. Incorporation of an unsubstituted benzimidazole moiety in place of a piperidine group afforded potent inhibitors of **MTP** in vitro which were weakly active in vivo. Appropriate substitution on the benzimidazole ring, especially with small alkyl groups, led to dramatic increases in potency, both in a cellular assay of apoB secretion and especially in animal models of cholesterol lowering. The most potent in this series, BMS-212122, was significantly more potent than BMS-201038 in reducing plasma lipids (cholesterol, VLDL/LDL, TG) in both hamsters and cynomolgus monkeys.

IT **194213-64-4P**

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(benzimidazole-based microsomal triglyceride transfer protein inhibitors)

RN 194213-64-4 HCAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[2,5-dimethyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **194213-62-2P 194213-63-3P 194213-66-6P**
194215-57-1P 194215-89-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzimidazole-based microsomal triglyceride transfer protein inhibitors)

RN 194213-62-2 HCAPLUS

CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194213-63-3 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194213-66-6 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[5-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194215-57-1 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-propyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194215-89-9 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-(1-methylethyl)-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **182431-12-5**, BMS 201038
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzimidazole-based microsomal triglyceride transfer protein inhibitors)
RN 182431-12-5 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:412194 HCAPLUS Full-text
DOCUMENT NUMBER: 133:38245
TITLE: Microsomal triglyceride transfer protein inhibitors as the medicine which decreases the blood level of lipoprotein a
INVENTOR(S): Chan, George; Hamanaka, Ernest Seiichi
PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000169395	A2	20000620	JP 1999-342833	19991202 <--
KR 2000047857	A	20000725	KR 1999-54413	19991202 <--
ZA 9907446	A	20010604	ZA 1999-7446	19991202 <--

PRIORITY APPLN. INFO.: US 1998-111100P P 19981204

AB Apolipoprotein B secretion substance/microsomal triglyceride transfer protein inhibitors, including 4'-trifluoromethylbiphenyl-2-carboxylic acid-[2-(1H-[1,2,4]triazol-3-ylmethy)-1,2,3,4-tetrahydroisoquinolin-6- yl]amide and others and their salts, are claimed as the medicine which decreases the blood level of lipoprotein a for mammals.

IT **182431-12-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(microsomal triglyceride transfer protein inhibitors as the medicine which decreases the blood level of lipoprotein a)

RN 182431-12-5 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L8 ANSWER 10 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:795595 HCAPLUS Full-text
DOCUMENT NUMBER: 132:35612
TITLE: Preparation of multibinding inhibitors of microsomal triglyceride transferase protein
INVENTOR(S): Griffin, John H.
PATENT ASSIGNEE(S): Advanced Medicine, Inc., USA
SOURCE: PCT Int. Appl., 181 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 31
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9963929	A2	19991216	WO 1999-US11789	19990604 <--
WO 9963929	A3	20000203		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2319495	AA	19991216	CA 1999-2319495	19990604 <--
EP 1085846	A2	20010328	EP 1999-928347	19990604 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6288234	B1	20010911	US 1999-325662	19990604 <--
SG 106036	A1	20040930	SG 1999-2845	19990607
SG 80631	A1	20010522	SG 1999-2719	19990608 <--
SG 90053	A1	20020723	SG 1999-2944	19990608 <--
US 6566509	B1	20030520	US 1999-327899	19990608
ZA 2000004086	A	20010810	ZA 2000-4086	20000810 <--
ZA 2000004558	A	20011130	ZA 2000-4558	20000831 <--
ZA 2000004559	A	20020402	ZA 2000-4559	20000831 <--
US 2002028943	A1	20020307	US 2001-760827	20010117 <--
US 2004023290	A1	20040205	US 2002-161279	20020603
US 2003176670	A1	20030918	US 2002-330381	20021227

PRIORITY APPLN. INFO.:

US 1998-88448P	P	19980608
US 1998-93072P	P	19980716
US 1999-325662	A3	19990604
WO 1999-US11789	W	19990604
US 1999-327899	A1	19990608
US 1999-328071	B1	19990608
US 2000-502938	A1	20000211

OTHER SOURCE(S): MARPAT 132:35612
GI



I

AB Disclosed are multibinding compds. which inhibit microsomal triglyceride transferase protein (**MTP**), a protein which mediates the transfer of lipids during the assembly of lipoproteins and related biomols. The multibinding compds. contain from 2 to 10 ligands covalently attached to one or more linkers. The multibinding compds. are useful for lowering serum lipid, cholesterol and/or triglyceride levels, and for preventing and treating disorders associated with hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypercholestrolemia, hypertriglyceridemia and the like, such as atherosclerosis.. The compds. may be identified, if desired, via combinatorial libraries based upon linkers and/or ligands. Examples include 21 prophetic syntheses of invention compds., outlines for several possible bioassays, and preparation details (with data) for several synthon/ligands. For instance, synthon/ligand I was prepared from the corresponding piperidine and 9-(bromobutyl)fluorene derivs.

IT **252361-13-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; multibinding inhibitors of microsomal triglyceride transferase protein)

RN 252361-13-0 HCAPLUS

CN Carbamic acid, [2-[[1-[4-[9-[[(2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-4-piperidinyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



PAGE 2-A



IT **252361-06-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthon; multibinding inhibitors of microsomal triglyceride transferase protein)
RN 252361-06-1 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[(2-aminoethyl)[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



●2 HCl

L8 ANSWER 11 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:193844 HCAPLUS Full-text
DOCUMENT NUMBER: 130:227739
TITLE: Method for lowering serum lipid levels employing an **MTP** inhibitor in combination with another cholesterol lowering drug
INVENTOR(S): Gregg, Richard E.; Pouleur, Hubert G.; Wetterau, John R., II
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: U.S., 22 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5883109	A	19990316	US 1997-854311	19970512 <--

PRIORITY APPLN. INFO.: US 1997-854311 19970512
OTHER SOURCE(S): MARPAT 130:227739

AB A method is provided for lowering serum lipids, cholesterol and/or triglycerides and thereby inhibiting atherosclerosis by administering to a patient an **MTP** inhibitor, in combination with a cholesterol lowering drug, such as pravastatin. Capsules were prepared containing about 5 mg **MTP** inhibitor BMS 201,038.

IT **182431-12-5**, BMS 201038 **202914-84-9**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lowering serum lipid levels employing an **MTP** inhibitor in combination with another cholesterol lowering drug)

RN 182431-12-5 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 202914-84-9 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 182431-12-5
CMF C39 H37 F6 N3 O2

PAGE 1-A



PAGE 2-A



CM 2

CRN 75-75-2
CMF C H4 O3 S



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:744939 HCAPLUS Full-text
DOCUMENT NUMBER: 130:17236
TITLE: **MTP** inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels
INVENTOR(S): Gregg, Richard E.; Wetterau, John R., II

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9850028	A1	19981112	WO 1998-US8269	19980423 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2286341	AA	19981112	CA 1998-2286341	19980423 <--
AU 9871559	A1	19981127	AU 1998-71559	19980423 <--
AU 748608	B2	20020606		
EP 1024804	A1	20000809	EP 1998-918680	19980423 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001527551	T2	20011225	JP 1998-548138	19980423 <--

PRIORITY APPLN. INFO.: US 1997-45405P P 19970501
WO 1998-US8269 W 19980423

OTHER SOURCE(S): MARPAT 130:17236

AB A pharmaceutical combination is formed from an **MTP** inhibitor and a fat soluble vitamin such as vitamins E, A, K and/or D, and optionally another cholesterol lowering drug, is provided which is employed in a method for lowering serum lipids, cholesterol and/or triglycerides and thereby inhibiting or treating atherosclerosis, pancreatitis, hyperglycemia and/or obesity. Tablets containing 500 mg clofibrate in combination with 10 mg BMS-201038 and fat soluble vitamins are employed in sep. dosage forma or combined in a single capsule form to lower cholesterol and treat various diseases.

IT **182431-12-5**, BMS 201238 **194213-62-2 194213-63-3 194213-64-4 194213-66-6 194213-67-7**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**MTP** inhibitors and fat soluble vitamin combinations to lower serum lipid levels)

RN 182431-12-5 HCAPLUS

CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194213-62-2 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194213-63-3 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194213-64-4 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2,5-dimethyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194213-66-6 HCAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[5-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194213-67-7 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[5-methoxy-2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:698031 HCAPLUS Full-text
DOCUMENT NUMBER: 130:76043
TITLE: An **MTP** inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits
AUTHOR(S): Wetterau, John R.; Gregg, Richard E.; Harrity, Thomas W.; Arbeeny, Cynthia; Cap, Michael; Connolly, Fergal; Chu, Ching-Hsuen; George, Rocco J.; Gordon, David A.; Jamil, Haris; Jolibois, Kern G.; Kunselman, Lori K.; Lan, Shih-Jung; Maccagnan, Thomas J.; Ricci, Beverly; Yan, Mujing; Young, Douglas; Chen, Ying; Fryszman, Olga M.; Logan, Janette V. H.; Musial, Christa L.; Poss, Michael A.; Robl, Jeffrey A.; Simpkins, Ligaya M.; Slusarchyk, William A.; Sulsky, Richard; Taunk,

Prakash; Magnin, David R.; Tino, Joseph A.; Lawrence, R. Michael; Dickson, John K., Jr.; Biller, Scott A.
CORPORATE SOURCE: Dep. Metabolic Diseases, Bristol-Myers Squibb Pharmaceutical Res. Inst., Princeton, NJ, 08543-4000, USA
SOURCE: Science (Washington, D. C.) (**1998**), 282(5389), 751-754
CODEN: SCIEAS; ISSN: 0036-8075
PUBLISHER: American Association for the Advancement of Science
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Patients with abetalipoproteinemia, a disease caused by defects in the microsomal triglyceride transfer protein (**MTP**), do not produce apolipoprotein B-containing lipoproteins. It was hypothesized that small mol. inhibitors of **MTP** would prevent the assembly and secretion of these atherogenic lipoproteins. To test this hypothesis, two compds. identified in a high-throughput screen for **MTP** inhibitors were used to direct the synthesis of a highly potent **MTP** inhibitor. This mol. (I) inhibited the production of lipoprotein particles in rodent models and normalized plasma lipoprotein levels in Watanabe-heritable hyperlipidemic (WHHL) rabbits, which are a model for human homozygous familial hypercholesterolemia. These results suggest that compound I, or derivs. thereof, has potential applications for the therapeutic lowering of atherogenic lipoprotein levels in humans.

IT **182431-12-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(microsomal triglyceride transfer protein (**MTP**) inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits in relation to anticholesterolemic activity and structure)

RN 182431-12-5 HCAPLUS

CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:509103 HCAPLUS Full-text
DOCUMENT NUMBER: 129:156944
TITLE: Method for treating acid lipase deficiency diseases with a microsomal triglyceride transfer protein (**MTP**) inhibitor and cholesterol lowering drug
INVENTOR(S): Gregg, Richard E.; Wetterau, John R., II
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9831367	A1	19980723	WO 1998-US619	19980113 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6066653	A	20000523	US 1998-5437	19980110 <--
AU 9861315	A1	19980807	AU 1998-61315	19980113 <--

PRIORITY APPLN. INFO.: US 1997-36183P P 19970117
WO 1998-US619 W 19980113

OTHER SOURCE(S): MARPAT 129:156944

AB A method is provided for inhibiting or treating diseases assocd. with acid lipase deficiency by administering to a patient an **MTP** inhibitor, alone or optionally, in combination with another cholesterol lowering drug, e.g. pravastatin.

IT **182431-12-5**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(acid lipase deficiency disease treatment with microsomal triglyceride transfer protein inhibitor and cholesterol lowering drug)

RN 182431-12-5 HCAPLUS

CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 15 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:509102 HCAPLUS Full-text
DOCUMENT NUMBER: 129:153237
TITLE: Method for treating atherosclerosis with an MPT inhibitor and cholesterol-lowering drugs
INVENTOR(S): Behounek, Bruce D.; Mcgovern, Mark E.; Belder, Rene
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9831366	A1	19980723	WO 1998-US524	19980112 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2276467	AA	19980723	CA 1998-2276467	19980112 <--
AU 9862397	A1	19980807	AU 1998-62397	19980112 <--
AU 727895	B2	20010104		
EP 989852	A1	20000405	EP 1998-904548	19980112 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001508795	T2	20010703	JP 1998-534460	19980112 <--

PRIORITY APPLN. INFO.: US 1997-35592P P 19970117
WO 1998-US524 W 19980112

OTHER SOURCE(S): MARPAT 129:153237

AB A method is provided for preventing or reducing the risk of onset of a cardiovascular event by administering an **MTP** (microsomal triglyceride transfer protein) inhibitor alone or in combination with another cholesterol lowering drug such as an HMG CoA reductase inhibitor such as pravastatin, to a patient who may or may not have one or more risk factors for a coronary and/or cerebrovascular event such as hypercholesterolemia. Capsules were prepared containing the **MTP** inhibitor BMS 201,038 and tablets were prepared containing cholesterol inhibitors and BMS 201,038 or BMS 201,238.

IT **182431-12-5**, BMS 201038
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating atherosclerosis with an MPT inhibitor and cholesterol-lowering drugs)

RN 182431-12-5 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 16 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:509064 HCAPLUS Full-text
DOCUMENT NUMBER: 129:144862
TITLE: Method for treating or inhibiting phytosterolemia with a microsomal triglyceride transfer protein (**MTP**) inhibitor and cholesterol lowering drug
INVENTOR(S): Gregg, Richard E.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9831225	A1	19980723	WO 1998-US618	19980113 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6057339	A	20000502	US 1998-5430	19980110 <--
AU 9860232	A1	19980807	AU 1998-60232	19980113 <--

PRIORITY APPLN. INFO.: US 1997-35591P P 19970117
WO 1998-US618 W 19980113

OTHER SOURCE(S): MARPAT 129:144862

AB A method is provided for inhibiting onset or treating phytosterolemia by administering to a patient an **MTP** inhibitor, alone or, optionally, in combination with another cholesterol lowering drug, e.g. pravastatin.

IT **182431-12-5**, BMS 201238
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phytosterolemia treatment with microsomal triglyceride transfer protein inhibitor and cholesterol lowering drug)

RN 182431-12-5 HCAPLUS

CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 17 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:372652 HCAPLUS Full-text
DOCUMENT NUMBER: 129:54368
TITLE: Preparation of 9-heterocyclylalkyl-9-fluorenecarboxamides and analogs as microsomal triglyceride transfer protein inhibitors
INVENTOR(S): Biller, Scott A.; Dickson, John K.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Robl, Jeffrey A.; Slusarchyk, William A.; Sulsky, Richard B.; Tino, Joseph A.

PATENT ASSIGNEE(S): USA
SOURCE: U.S., 240 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5760246	A	19980602	US 1996-767923	19961217 <--
US 6472414	B1	20021029	US 1999-313883	19990518 <--

PRIORITY APPLN. INFO.: US 1996-767923 A1 19961217
US 1997-802705 B1 19970219

OTHER SOURCE(S): MARPAT 129:54368
GI



I

AB Title compds., e.g., R1Z1BCOAZ2R2 [A = bond, O, (alkyl)imino; B = e.g., C(ZR)2 in which RR = bond, O, NH, alk(en)ylene, etc., and Z = (un)substituted 1,2-phenylene; R1 = H, alk(en)yl, (hetero)aryl, etc.; R1 = groups cited for R1, haloalkyl, etc.; Z1 = (oxo- or aza)(oxo)alk(en)ylene, etc.; Z2 = bond, groups cited forZ1, etc.] were prepared as microsomal triglyceride transfer protein inhibitors (no data). Thus, 9-fluorenecarboxylic acid was alkylated by Br(CH2)4Br and the CF3CH2NH2-amidated product arylated by 4-nitroimidazole to give, after reduction and N-acylation, title compd I.

IT **194213-62-2P 194213-63-3P 194213-64-4P**
194213-66-6P 194213-67-7P 194213-91-7P
194213-92-8P 194214-93-2P 194215-13-9P
194215-57-1P 194215-59-3P 194215-61-7P
194215-63-9P 194215-65-1P 194215-84-4P
194215-89-9P 194216-08-5P 194216-15-4P
194216-16-5P 194216-17-6P 194216-19-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 9-heterocyclylalkyl-9-fluorenecarboxamides and analogs as microsomal triglyceride transfer protein inhibitors)

RN 194213-62-2 HCAPLUS

CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194213-63-3 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194213-64-4 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2,5-dimethyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194213-66-6 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[5-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194213-67-7 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[5-methoxy-2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194213-91-7 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-(4-morpholinyl)-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194213-92-8 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-methyl-4-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194214-93-2 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2,3-dihydro-2-oxo-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194215-13-9 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[(3'-chloro[1,1'-biphenyl]-2-yl)carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194215-57-1 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-propyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194215-59-3 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-(diethylamino)-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194215-61-7 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-methoxy-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194215-63-9 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-(methylthio)-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194215-65-1 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-chloro-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194215-84-4 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194215-89-9 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-(1-methylethyl)-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194216-08-5 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[(4'-chloro[1,1'-biphenyl]-2-yl)carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194216-15-4 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethoxy)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194216-16-5 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[[3',5'-bis(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194216-17-6 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[3'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194216-19-8 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-methyl-4-[[[3'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 18 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:236274 HCAPLUS Full-text
DOCUMENT NUMBER: 128:282780
TITLE: Preparation of heterocyclic inhibitors of microsomal triglyceride transfer protein
INVENTOR(S): Biller, Scott A.; Dickson, John K.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Sulsky, Richard B.; Tino, Joseph A.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: U.S., 185 pp., Cont.-in-part of U.S. Ser. No. 391,901, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 5739135	A	19980414	US 1995-472067	19950606	<--
CA 2091102	AA	19930907	CA 1993-2091102	19930305	<--
HU 67962	A2	19950529	HU 1993-627	19930305	<--
HU 218419	B	20000828			
JP 06038761	A2	19940215	JP 1993-46499	19930308	<--
EP 584446	A2	19940302	EP 1993-103697	19930308	<--
EP 584446	A3	19950426			
EP 584446	B1	20020619			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
AT 219514	E	20020715	AT 1993-103697	19930308	<--
PT 584446	T	20020930	PT 1993-103697	19930308	<--
ES 2178640	T3	20030101	ES 1993-103697	19930308	<--
AU 670930	B2	19960808	AU 1993-34064	19930309	<--
AU 9334064	A1	19930909			
US 5595872	A	19970121	US 1993-117362	19930903	<--
US 5789197	A	19980804	US 1995-486924	19950607	<--
US 6492365	B1	20021210	US 1995-486929	19950607	<--
US 5712279	A	19980127	US 1996-548811	19960111	<--
IL 116917	A1	20000831	IL 1996-116917	19960126	<--
TW 486469	B	20020511	TW 1996-85100978	19960126	<--
CA 2213466	AA	19960829	CA 1996-2213466	19960201	<--
WO 9626205	A1	19960829	WO 1996-US824	19960201	<--
W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
AU 9647631	A1	19960911	AU 1996-47631	19960201	<--
AU 699865	B2	19981217			
CN 1176640	A	19980318	CN 1996-192015	19960201	<--
CN 1108301	B	20030514			
EP 886637	A1	19981230	EP 1996-903604	19960201	<--
EP 886637	B1	20041201			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE					
JP 11500442	T2	19990112	JP 1996-525679	19960201	<--
NZ 302055	A	20000228	NZ 1996-302055	19960201	<--
PL 185443	B1	20030530	PL 1996-322003	19960201	
AT 283851	E	20041215	AT 1996-903604	19960201	
ZA 9601340	A	19970911	ZA 1996-1340	19960220	<--
US 5883099	A	19990316	US 1997-896872	19970721	<--
US 6034098	A	20000307	US 1997-898304	19970721	<--
US 6066650	A	20000523	US 1997-898303	19970721	<--
FI 9703416	A	19970820	FI 1997-3416	19970820	<--
NO 9703821	A	19970820	NO 1997-3821	19970820	<--
LT 4367	B	19980825	LT 1997-152	19970919	<--
LV 11951	B	19981120	LV 1997-171	19970919	<--
US 2003166590	A1	20030904	US 2001-933593	20010821	

PRIORITY APPLN. INFO.:	US 1993-117362	A2	19930903
	US 1994-284808	B2	19940805
	US 1995-391901	B2	19950221
	US 1992-847503	A	19920306
	US 1993-15449	B2	19930222
	US 1995-472067	A2	19950606
	US 1995-486929	A3	19950607
	WO 1996-US824	W	19960201

OTHER SOURCE(S): MARPAT 128:282780
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I-V; Q = C(O), S(O)2; X = CHR8, C(O), CHR9CHR10, CR9:CR10 (wherein R8-R10 = H, alkyl, alkenyl, etc.); Y = (CH2)m, C(O) (m = 2-3); R1 = alkyl, alkenyl, alkynyl, etc.; R2-R4 = H, halo, alkyl, etc.; R5 = alkyl, alkenyl, alkynyl, etc.; R6 = H, C1-4 alkyl, C1-4 alkenyl] which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases such as hyperglycemia and obesity, were prepared Thus, reaction of 1-(3,3-diphenylpropyl)-4-piperidinamine.HCl (preparation described) with benzoyl chloride in the presence of Et3N in CH2Cl2 afforded 84% the title compound III.HCl [Q = C(O); R1 = 3,3-diphenylpropyl; R5 = Ph; R6 = H]. Compds. I-V are effective at 5-500 mg/day.

IT **182429-77-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic inhibitors of microsomal triglyceride transfer protein)

RN 182429-77-2 HCAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[([1,1'-biphenyl]-2-ylcarbonyl)amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 19 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:115356 HCAPLUS Full-text
DOCUMENT NUMBER: 128:154011
TITLE: Preparation of 9-thioxanthenecarboxamides and 9-fluorenecarboxamides as inhibitors of microsomal triglyceride transfer protein
INVENTOR(S): Biller, Scott A.; Dickson, John K.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Robl, Jeffrey A.; Sulsky, Richard B.; Tino, Joseph A.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: U.S., 98 pp., Cont.-in-part of U. S. Ser. No.472,067.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 5712279	A	19980127	US 1996-548811	19960111	<--
CA 2091102	AA	19930907	CA 1993-2091102	19930305	<--
HU 67962	A2	19950529	HU 1993-627	19930305	<--
HU 218419	B	20000828			
JP 06038761	A2	19940215	JP 1993-46499	19930308	<--
EP 584446	A2	19940302	EP 1993-103697	19930308	<--
EP 584446	A3	19950426			
EP 584446	B1	20020619			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
AT 219514	E	20020715	AT 1993-103697	19930308	<--
PT 584446	T	20020930	PT 1993-103697	19930308	<--
ES 2178640	T3	20030101	ES 1993-103697	19930308	<--
AU 670930	B2	19960808	AU 1993-34064	19930309	<--
AU 9334064	A1	19930909			
US 5739135	A	19980414	US 1995-472067	19950606	<--
ZA 9601340	A	19970911	ZA 1996-1340	19960220	<--
LT 4367	B	19980825	LT 1997-152	19970919	<--

PRIORITY APPLN. INFO.:
US 1995-391901 B2 19950221
US 1995-472067 A2 19950606
US 1992-847503 A 19920306
US 1993-117362 A2 19930903
US 1994-284808 B2 19940805

OTHER SOURCE(S): MARPAT 128:154011
GI



I



II



III

AB The title compds. [I; Z = a bond, S; X1, X2 = H, halo; x = 2-6; (CH2)x is optionally substituted with 1-3 substituents such as alkyl or halo; R5 = (un)substituted heteroaryl, aryl, heterocycloalkyl, cycloalkyl] and their piperidine N-oxides, which inhibit microsomal triglyceride transfer protein and thus are useful for preventing or treating atherosclerosis, pancreatitis secondary to hypertriglyceridemia, hyperglycemia, or obesity, and for lowering serum lipid levels, or preventing and/or treating hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, and/or hypertriglyceridemia, were prepared Thus, reaction of 9-fluorenecarboxamide II (preparation of both reagents is described) with piperidine III in PhMe/DMF afforded the title compound I [Z = a bond; X1 = X2 = H; (CH2)x = (CH2)2CF2CH2; R5 = 2-biphenyl]. Compds. I are effective at 5-500 mg/day.

IT **182430-91-7P 182430-92-8P 182430-95-1P**
182430-96-2P 182430-98-4P 182431-10-3P
182431-12-5P 182431-17-0P 182431-21-6P
182431-39-6P 182431-48-7P 182431-51-2P
182431-68-1P 182431-69-2P 182432-02-6P
182434-83-9P 182434-99-7P 182435-10-5P
182438-13-7P 182438-14-8P 182438-15-9P
202522-42-7P 202523-11-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 9-thioxanthenecarboxamides and 9-fluorenecarboxamides as inhibitors of microsomal triglyceride transfer protein)

RN 182430-91-7 HCAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[(4'-chloro[1,1'-biphenyl]-2-yl)carbonyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 182430-92-8 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[(4'-chloro[1,1'-biphenyl]-2-yl)carbonyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 182430-95-1 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 182430-96-2 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-, (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 182430-98-4 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[1-oxido-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 182431-10-3 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 182431-12-5 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 182431-17-0 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[([1,1'-biphenyl]-2-ylcarbonyl)amino]-1-piperidinyl]-3,3-dimethylbutyl]-N-(2,2,2-trifluoroethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl

RN 182431-21-6 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[([1,1'-biphenyl]-2-ylcarbonyl)amino]-1-piperidinyl]-3-hydroxybutyl]-N-(2,2,2-trifluoroethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl

RN 182431-39-6 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[(2',4'-dichloro[1,1'-biphenyl]-2-yl)carbonyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 182431-48-7 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[(4,4'-difluoro[1,1'-biphenyl]-2-yl)carbonyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 182431-51-2 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[(4-chloro[1,1'-biphenyl]-2-yl)carbonyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl

RN 182431-68-1 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[[4-chloro-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl

RN 182431-69-2 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[[4-chloro-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-oxido-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 182432-02-6 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[(4'-fluoro[1,1'-biphenyl]-2-yl)carbonyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 182434-83-9 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[([1,1'-biphenyl]-2-ylcarbonyl)amino]-1-piperidinyl]-3-hydroxybutyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 182434-99-7 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[[4-chloro-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 182435-10-5 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[([1,1'-biphenyl]-2-ylcarbonyl)amino]-1-piperidinyl]-3,3-difluorobutyl]-N-(2,2,2-trifluoroethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl

RN 182438-13-7 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[([1,1'-biphenyl]-2-ylcarbonyl)amino]-1-piperidinyl]-3,3-difluorobutyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 182438-14-8 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[(4,4'-difluoro[1,1'-biphenyl]-2-yl)carbonyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI)

(CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 182438-15-9 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[(4-chloro[1,1'-biphenyl]-2-yl)carbonyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 202522-42-7 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[(2',4'-dichloro[1,1'-biphenyl]-2-yl)carbonyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 202523-11-3 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[([1,1'-biphenyl]-2-ylcarbonyl)amino]-1-oxido-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 20 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:87611 HCAPLUS Full-text
DOCUMENT NUMBER: 128:149575
TITLE: Method for treating tumors having high LDL requirements employing delipidating agents such as microsomal triglyceride-transfer protein (**MTP**) inhibitors
INVENTOR(S): Firestone, Raymond A.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9803174	A1	19980129	WO 1997-US12158	19970714 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2261162	AA	19980129	CA 1997-2261162	19970714 <--
AU 9736008	A1	19980210	AU 1997-36008	19970714 <--
AU 712303	B2	19991104		
EP 954313	A1	19991110	EP 1997-932594	19970714 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: US 1996-22863P P 19960724
WO 1997-US12158 W 19970714

OTHER SOURCE(S): MARPAT 128:149575

AB A method is provided for treating hematol. tumors and solid tumors, including certain types of leukemias and metastatic tumors, having high LDL requirements employing a delipidating agent such as an **MTP** inhibitor to substantially reduce LDL blood levels. In addition, a method is provided for treating tumors of the above types having high LDL requirements, especially hematol. tumors such as certain leukemias, employing a delipidating compound to substantially remove native LDL, and then administering a cytotoxic agent carried in reconstituted LDL.

IT **182431-12-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(delipidating agent such as **MTP** inhibitor for treatment of tumor with high LDL requirement)

RN 182431-12-5 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 21 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:87580 HCAPLUS Full-text
DOCUMENT NUMBER: 128:162883
TITLE: Method for lowering serum lipid levels employing a microsomal triglyceride-transfer protein (**MTP**) inhibitor in combination with another cholesterol-lowering drug
INVENTOR(S): Gregg, Richard E.; Pouleur, Hubert G.; Wetterau, John R., II
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9803069	A1	19980129	WO 1997-US12229	19970714 <--

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

ZA 9705950	A	19990104	ZA 1997-5950		19970703 <--
CA 2260995	AA	19980129	CA 1997-2260995		19970714 <--
AU 9736624	A1	19980210	AU 1997-36624		19970714 <--
AU 716145	B2	20000217			
EP 1014791	A1	20000705	EP 1997-933435		19970714 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
JP 2000515526	T2	20001121	JP 1998-507023		19970714 <--
PRIORITY APPLN. INFO.:			US 1996-22866P	P	19960724
			WO 1997-US12229	W	19970714

OTHER SOURCE(S): MARPAT 128:162883

AB A method is provided for lowering serum lipids, cholesterol, and/or triglycerides and thereby inhibiting atherosclerosis by administering to a patient an **MTP** inhibitor in combination with a cholesterol lowering drug, e.g. pravastatin.

IT **182431-12-5 202914-84-9**, BMS 201038 methanesulfonic acid salt
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(microsomal triglyceride-transfer protein (**MTP**) inhibitor combination with cholesterol-lowering drug for lowering serum lipid level)

RN 182431-12-5 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 202914-84-9 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-

(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 182431-12-5
CMF C39 H37 F6 N3 O2

PAGE 1-A



PAGE 2-A



CM 2

CRN 75-75-2
CMF C H4 O3 S



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 22 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:499168 HCAPLUS Full-text
DOCUMENT NUMBER: 127:190649
TITLE: Preparation of 9-aralkyl-9-fluorenecarboxamides and

analogs as microsomal triglyceride transfer protein inhibitors

INVENTOR(S): Biller, Scott A.; Dickson, John K.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Robl, Jeffrey A.; Slusarchyk, William A.; Sulsky, Richard B.; Tino, Joseph A.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA

SOURCE: PCT Int. Appl., 615 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9726240	A1	19970724	WO 1997-US587	19970113 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2236684	AA	19970724	CA 1997-2236684	19970113 <--
AU 9718285	A1	19970811	AU 1997-18285	19970113 <--
AU 716729	B2	20000302		
CN 1209803	A	19990303	CN 1997-191713	19970113 <--
EP 904262	A1	19990331	EP 1997-903805	19970113 <--
EP 904262	B1	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9707607	A	19990727	BR 1997-7607	19970113 <--
JP 2000502355	T2	20000229	JP 1997-526127	19970113 <--
NZ 330216	A	20000929	NZ 1997-330216	19970113 <--
AT 264833	E	20040515	AT 1997-903805	19970113
ES 2218660	T3	20041116	ES 1997-903805	19970113
ZA 9700328	A	19970715	ZA 1997-328	19970115 <--
NO 9803268	A	19980715	NO 1998-3268	19980715 <--

PRIORITY APPLN. INFO.:

US 1996-10346P	P	19960116
US 1996-17224P	P	19960509
US 1996-30370P	P	19961105
WO 1997-US587	W	19970113

OTHER SOURCE(S): MARPAT 127:190649

GI



I

AB R2Z4Z3ZZ2Z1R1 [R1 = H, (cyclo)alk(en)yl, alkoxy, (hetero)aryl(oxy), etc.; R2 = groups cited for R1, haloalkyl, etc.; Z = CO, SO0-2, CR(OH); R = H, alkyl, aryl; Z1 = (O- or NH-interrupted)(oxo)alk(en)ylene, etc.; Z2 = (un)substituted 9H-fluoren-9-ylidene, 9H-xanthen-9-ylidene, etc.; Z3 = bond, O, NR5; R5 = H or alkyl; R2R5 = atoms to form a ring; Z4 = bond, groups cited for Z1] were prepd as microsomal triglyceride transfer protein inhibitors (no data). Thus, 9H-fluorene-9-carboxylic acid was alkylated by TsOCH2CH2C.tplbond.CH and the product amidated by H2NCH2CF3 9-(3-butynyl)-N-(2,2,2-trifluoroethyl)fluorene-9-carboxamide which was arylated by 2-bromo-5-nitropyridine to give, after reduction and BzCl amidation, title compound I.

IT **194213-62-2P 194213-63-3P 194213-64-4P**
194213-66-6P 194213-67-7P 194213-91-7P
194213-92-8P 194214-93-2P 194215-13-9P
194215-57-1P 194215-59-3P 194215-61-7P
194215-63-9P 194215-65-1P 194215-84-4P
194215-89-9P 194216-08-5P 194216-15-4P
194216-16-5P 194216-17-6P 194216-19-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 9-aralkyl-9-fluorenecarboxamides and analogs as microsomal triglyceride transfer protein inhibitors)

RN 194213-62-2 HCAPLUS

CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194213-63-3 HCAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-

trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194213-64-4 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2,5-dimethyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194213-66-6 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[5-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194213-67-7 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[5-methoxy-2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194213-91-7 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-(4-morpholinyl)-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194213-92-8 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-methyl-4-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 1-A



PAGE 2-A



RN 194215-13-9 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[(3'-chloro[1,1'-biphenyl]-2-yl)carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194215-57-1 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-propyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194215-59-3 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-(diethylamino)-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194215-61-7 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-methoxy-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194215-63-9 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-(methylthio)-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194215-65-1 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-chloro-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194215-84-4 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[methyl[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194215-89-9 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-(1-methylethyl)-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194216-08-5 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[(4'-chloro[1,1'-biphenyl]-2-yl)carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194216-15-4 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethoxy)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194216-16-5 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[[3',5'-bis(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194216-17-6 HCAPLUS
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[3'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 194216-19-8 HCAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[2-methyl-4-[[[3'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




O
F3C— CH2— NH— C
R